Aptose Biosciences Announces Exclusive License Agreement for Dual BET/Kinase Targeting Program With OHM Oncology

Mar 07, 2018 7:00am EST

Aptose to Participate in Upcoming Investor Conferences In March 2018

Mar 06, 2018 7:00am EST

Aptose Biosciences Files New Preliminary Base Shelf Prospectus to Replace Expired Base Prospectus

Feb 07, 2018 4:01pm EST

Aptose Biosciences to Present at Biotech Showcase™ 2018 Conference

Jan 02, 2018 7:30am EST

FDA Grants Orphan Drug Designation to Aptose Biosciences for CG’806 in Acute Myeloid Leukemia

Dec 26, 2017 7:30am EST

Aptose Presents New Preclinical Data on CG’806 pan-FLT3/pan-BTK Inhibitor at ASH 59th Annual Meeting

Dec 11, 2017 4:04pm EST

OHSU and Aptose Present CG’806 Preclinical Data at ASH 59th Annual Meeting

Dec 11, 2017 4:04pm EST

Aptose Reports Results for the Third Quarter Ended September 30, 2017

Nov 14, 2017 4:00pm EST

Aptose To Release Third Quarter Ended September 30, 2017 Financial Results and Hold Conference Call on November 14, 2017

Nov 07, 2017 8:00am EST

Aptose to Present New CG’806 Data at the 2017 ASH Annual Meeting

Nov 01, 2017 11:14am EDT